本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
台北—2025年6月4日—今年是首款商用現場可程式化邏輯閘陣列（FPGA）問世 40週年，該技術引入「可重複程式化硬體」的概念。藉由打造「如同軟體般靈活的硬體」，FPGA可重複程式化的邏輯改變了半導體設計的面貌。這是工程師首度能在設計晶片時，如果規格或需求在中途、甚至在製造完成後發生變化，依然可以重新定義晶片功能來執行不同任務。這項靈活性加快了晶片設計的開發速度，縮短產品上市時程，並成為應用特定積體電路（ASIC）的替代方案。 FPGA對市場影響深遠，催生了一個價值超過100億美元的產業。在過去40年間，我們已向全球超過7,000家客戶橫跨不同的市場領域交付超過30億顆FPGA與自行調適SoC（結合FPGA架構、系統單晶片與其他處理引擎的裝置）。事實上，我們已連續25年在可程式化邏輯市場維持領先地位，憑藉著強大的產品陣容與發展藍圖，我們有信心能持續領先市場。 加速創新 FPGA是由已故的Ross Freeman發明，他是賽靈思公司（現為AMD一部分）共同創辦人，也是一位工程師與創新者。Freeman認為，除了標準的固定功能ASIC元件外，一定存在更好、更具成本效益的晶片設計方式。FPGA提供工程師隨時修改晶片設計的自由與靈活性，甚至能在一天之內完成一款客製晶片的開發與設計。FPGA同時也推動「無晶圓廠」（fabless）商業模式，顛覆整個半導體產業。藉由消除對客製光罩製作（mask tooling）與相關非經常性工程成本的依賴，FPGA推動硬體創新，證明企業無需擁有晶圓廠，只需具備願景、設計能力與 FPGA，即可打造突破性硬體。 Ross Freeman（右）俯瞰XC2064設計 全球首款商用FPGA－XC2064，擁有85,000個電晶體、64個可配置邏輯區塊與58個I/O區塊。相比之下，今日最先進的AMD FPGA（如Versal Premium VP1902）整合了1,380億個電晶體、1,850萬個邏輯單元、2,654個I/O區塊、高達6,864個DSP58引擎，以及大量應用於記憶體、安全與介面技術的硬體IP。 自全球首款商用FPGA（XC2064）問世至今已40年，FPGA已無所不在應用於電子產業，深入我們日常生活。如今，FPGA、自行調適SoC和系統模組（SOM）等自行調適運算裝置，已遍佈各種領域：從汽車、火車車廂、交通號誌，到機器人、無人機、太空船與衛星，再到無線網路、醫療與測試設備、智慧工廠、資料中心，甚至高頻交易系統等。 關鍵創新與產品里程碑 40多年來，AMD的創新與不斷演進的市場需求推動著FPGA技術歷經多項突破： ․ 1985年：XC2064－首款商用FPGA。 ․ 1990年代：XC4000與Virtex™ FPGA－首次將嵌入式RAM與DSP整合於無線通訊基礎設施。 ․ 1999年：Spartan系列問世－為大容量應用提供高成本效益的傳統ASIC替代方案。 ․ 2001年：首款整合SerDes的FPGA。 ․ 2011年：Virtex-7 2000T成為業界首個採用CoWoS封裝的量產部署－開創先進的2.5D整合技術之採用，現已成為高效能運算（HPC）與AI GPU的核心。 ․ 2012年：Zynq系列－首款將Arm CPU與可程式化邏輯結合的自行調適SoC。 ․ 2012年：Vivado™設計套件－讓軟體開發者也能設計FPGA。 ․ 2019年：首款Versal自行調適SoC問世－引入專屬的AI引擎與可程式化晶片上網路（NoC）。 ․ 2019年：Vitis™統一軟體平台推出－提供預先最佳化的AI工具與抽象層，加速AI推論。 ․ 2024年：第2代Versal AI Edge系列－將可程式化邏輯、CPU、DSP與AI引擎整合於單一晶片，首次實現端對端AI加速，為新一代需要異質、高效率、低延遲的應用提供支援。 ․ 2024年：Spartan UltraScale+ FPGA系列－強化成本最佳化型FPGA與自行調適SoC產品線，為邊緣I/O密集型應用提供高效率且經濟的解決方案。 Vivado與Vitis軟體的推出，對擴大市場具有重大意義。Vivado軟體提供高階合成、機器學習最佳化與無縫IP核心整合功能，幫助開發人員簡化工作流程、縮短開發週期並提升效能。 Vitis™開發環境則提供預先最佳化工具與抽象層以加速AI推論。最新版本（2024.2）引入了多項新功能，例如針對嵌入式C/C++設計的獨立工具，以及簡化AMD Versal自行調適SoC AI引擎部署的改良功能。我們將持續投入於這些工具，提升使用者的工作效率，同時支援新興與多樣化的資料類型與AI模型。 FPGA技術的演變 FPGA技術的演進：邁向邊緣AI 目前大部分AI工作負載都在資料中心GPU上運行。然而，愈來愈多AI處理正在邊緣發生。FPGA技術正站在這波AI融合應用快速發展的最前線。FPGA與自行調適SoC能即時處理感測器資料，實現低延遲的加速邊緣AI推論。隨著小型生成式AI模型的問世，「ChatGPT時刻」正邁向邊緣設備，讓AI模型能執行於如AI PC、車輛、工廠機器人、太空任務或任何嵌入式裝置中。 以下是AMD自行調適運算技術如何支援邊緣AI工作負載的實際案例： ․ 美國太空總署（NASA）－AMD Virtex FPGA協助NASA火星探測車執行AI圖像辨識、比對與校正，並在回傳地球前過濾無用資料。此外，最新的太空等級Versal AI Edge自行調適SoC將加速的AI推論帶入太空，並具有對ML應用最佳化的增強型AI引擎。 ․ Subaru－採用第2代Versal AI Edge SoC，為下一代ADAS “EyeSight”駕駛輔助系統導入AI功能。 ․ SICK－透過AMD Kintex™ UltraScale+™ FPGA搭配FINN機器學習框架，提升工廠自動化與包裹檢查效率。 ․ Radmantis－採用AMD Kria™自行調適SOM裝置，推動永續漁業發展並執行即時AI推論。 ․ JR九州－日本最大子彈列車營運商之一，採用AMD Kria SOM執行即時影像處理，用於AI化的軌道檢測系統。 ․ Clarius－在其手持式超音波設備中，透過AMD Zynq UltraScale自行調適SoC執行區域AI辨識。 展望未來 我們預期FPGA的自行調適運算技術，將持續在自動駕駛、機器人與工業自動化、6G通訊、氣候變遷、藥物研發、科學研究與太空探索等領域推動邊緣AI應用的突破。FPGA問世40週年之際，回顧40年帶來深遠的影響，我們對這項技術的發明深感驕傲。致力於頂尖與領先市場產品的開發者，將持續運用FPGA推動創新晶片設計、支援硬體輔助驗證並加快產品上市腳步。AMD承諾未來將致力於持續引領這項關鍵技術的發展。
EBC-129 is an antibody-drug conjugate (ADC) that selectively targets a novel, tumour-specific N-glycosylated epitope found on both CEACAM5 and CEACAM6. The expansion cohort for pancreatic ductal adenocarcinoma (PDAC) in the ongoing Phase 1 trial has completed enrolment. Notably, 82% of patients had tumours expressing the antigen at levels considered treatable with EBC-129. EBC-129 demonstrated positive overall response rates and prolonged progression-free survival in PDAC patients that have been heavily pre-treated, including those that have received prior treatment with standard of care (SoC) typically containing taxanes. The US FDA also recently granted Fast Track Designation for EBC-129 in the treatment of PDAC patients. SINGAPORE, June 3, 2025 /PRNewswire/ -- The Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development, has announced the presentation of updated clinical data for the ongoing Phase 1 trial for EBC-129 at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. EBC-129 is a first-in-class antibody drug conjugate (ADC) targeting a novel, tumour-specific N256-glycosylated epitope on CEACAM5 and CEACAM6. The updated findings showed promising efficacy data from 21 heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patients across the dose escalation and the dose expansion portions of the Phase 1 study. Patients received EBC-129 at doses between 1.8 and 2.2 mg/kg, given once every 3 weeks. 17 out of 21 patients (81%) of the patients had received prior treatment with taxanes. 82% of patients had tumours which expressed the EBC-129 antigen at ≥1% at 3+ intensity and were therefore considered treatable. The overall response rates (ORRs) were 25% and 20%, with disease control rates (DCRs) of 87.5% and 63.6% and progression-free survival (PFS) of 19 and 12 weeks for 1.8 mg/kg and 2.2 mg/kg, respectively. "Pancreatic adenocarcinoma remains one of the most challenging cancers to treat, particularly in the metastatic setting where resistance to standard therapies is common. The clinical signals observed with EBC-129 in refractory pancreatic adenocarcinoma, including tolerability, prolonged disease control and a confirmed response in a heavily pre-treated patient, are encouraging and clinically meaningful. Continued prioritisation of biology-guided trials targeting EBC-129 will be key to sustaining momentum in this important therapeutic effort," said Assistant Professor Robert W. Lentz, MD, Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz School of Medicine. This presentation follows the recent Fast Track Designation granted by the U.S. FDA for EBC-129 in the treatment of PDAC patients. This designation supports EDDC's efforts to accelerate the advancement of the programme through increased regulatory engagement and the potential for expedited review pathways. Other Results to Date The dose escalation study of the Phase 1 trial was open to all patients, while the ongoing dose expansion study comprises of three cohorts in PDAC, gastroesophageal adenocarcinoma (GEA) and tumour-agnostic patients with other immunohistochemistry (IHC)-positive solid tumours. Recruitment for the GEA and IHC-positive cohorts is still ongoing. EBC-129 showed a manageable safety profile in the 58 patients treated so far, with uncomplicated neutropenia and infusion-related reactions as the main treatment-related adverse events (TRAEs) observed. The EBC-129 antigen was also found to be highly expressed, with 52% to 100% of tumour tissues assessed during the trial showing moderate to high expression levels of ≥20% at 2+ and/or 3+. This included samples from gastroesophageal, appendiceal, colorectal and lung cancer patients, making EBC-129 a potentially viable treatment option for these cancers. "We have seen encouraging signs of efficacy of EBC-129 as a single-agent therapy, even in heavily pre-treated patients with metastatic pancreatic cancer. This, combined with the observed safety profile, underscores the promise of EBC-129 as a possible treatment option for PDAC patients. As a first-in-class ADC that targets both CEACAM5 and CEACAM6, EBC-129 has also shown potential against a range of other solid tumours, and we look forward to expanding clinical evaluations with the ongoing dose expansion cohorts and accelerating the development of EBC-129 to address critical unmet needs in cancer," said Professor Damian O'Connell, CEO of EDDC. About EBC-129 EBC-129 is an ADC that targets a tumour-specific N256-glycosylation site conserved on CEACAM5 and CEACAM6. CEACAM5 and CEACAM6 are known to have functional importance in tumour formation, migration and metastasis. In the ongoing trial, the tumour-specific marker is found to be widely expressed in multiple solid tumour types, including gastric, oesophageal, pancreatic, lung, colorectal, and appendiceal cancers, based on an analytically validated immunohistochemistry (IHC) assay. The payload used in EBC-129 is monomethyl auristatin E (MMAE), which has been extensively tested and approved for clinical use in other marketed ADCs, and has demonstrated synergy with PD-1 inhibitors. The ongoing Phase 1 trial of EBC-129 is assessing the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours. Enrolment for the PDAC cohort in the Phase 1 dose expansion study is now complete, while recruitment continues for the gastroesophageal adenocarcinoma (GEA) and IHC-positive cohorts. For information about the trial, please visit Clinicaltrial.gov, trial identifier NCT05701527. About the Experimental Drug Development Centre The Experimental Drug Development Centre (EDDC) is Singapore's national platform for drug discovery and development, formed from the integration of the Experimental Therapeutics Centre (ETC), Drug Discovery and Development (D3), and Experimental Biotherapeutics Centre (EBC) in 2019. EDDC aims to develop therapeutics and diagnostics that save and improve the lives of patients in Singapore, Asia and around the world. Hosted by the Agency for Science, Technology and Research (A*STAR), EDDC works collaboratively with public sector and industry partners to translate the great science arising from Singapore's biomedical and clinical sciences R&D into innovative healthcare solutions. For more information about EDDC, please visit www.eddc.sg.
HONG KONG, June 2, 2025 /PRNewswire/ -- OSL has introduced access to sUSDe for eligible investors through its over-the-counter (OTC) desk. This initiative, spearheaded by OSL Wealth, leverages the firm's regulated infrastructure to deliver seamless trading and institutional-grade custody solutions. Tony Luk, Head of OSL Wealth, commented: "Our clients are looking for dollar stability with real, sustainable returns—delivered through a trusted institution. By integrating sUSDe into OSL's robust compliance, custody, and security framework, we've transformed a technically complex DeFi strategy into a simple, secure solution." Steven Shi, Head of Institutional Growth at Ethena Labs, added: "As one of the leading licensed entities providing digital asset services, OSL is an ideal partner for us. OSL Wealth's adoption of sUSDe brings our globally accessible dollar-based savings asset to clients who demand both transparency and institutional-grade security." This launch marks a continued effort by OSL Wealth to bridge innovative DeFi solutions with the needs of institutional and professional investors in a secure, regulated environment. About OSL Group OSL Group (HKEX: 863.HK) is a leading global financial infrastructure platform bridging traditional finance and the digital asset economy through blockchain technology. The Group is dedicated to providing efficient, seamless, and regulatory-compliant financial services to individuals and businesses worldwide. OSL delivers a comprehensive suite of regulated services through its licensed platforms, including 24/7 OTC brokerage with deep liquidity fiat gateways and competitive pricing; omnibus brokerage solutions enabling traditional financial institutions to integrate digital assets; SOC 2 Type 2-certified custody with up to US$1 billion insurance protection; and compliant retail trading channels; wealth management solutions, including scheduled launches on tokenised treasuries and RWAs; and in preparation for cross-border payment infrastructure via OSL Pay. "Open, Secure, Licensed" are the principles OSL lives by. OSL is expanding its compliant infrastructure across Japan, Australia, and Europe, potentially Southeast Asia, powering the next generation of global financial infrastructure. For more information, please visit group.osl.com. About Ethena Labs Ethena is the protocol behind USDe, the third-largest and fastest growing USD-denominated crypto asset in history. Ethena has $6.2 billion in TVL today, alongside integrations with some of the largest centralized exchanges and major DeFi applications. Ethena Labs, a contributor to the protocol, is backed by Fidelity, Franklin Templeton, Dragonfly, Binance Labs, Bybit and OKX among others.
SINGAPORE, May 30, 2025 /PRNewswire/ -- From May 27-29, Black Sesame Technologies (Stock Code: 2533.HK), a leading automotive-grade computing SoC and Soc-based intelligent vehicle solution provider, made its grand debut at Asia Tech x Singapore (ATxSG) at the Singapore EXPO Convention Center. In the TechXLR8Asia zone (Booth 4N2-5) dedicated to AI, IoT and edge computing, the company showcased its full-stack solutions for robotics, advanced driver assistance systems (ADAS), and edge intelligence. Black Sesame Technologies Exhibition Booth Leveraging years of expertise in the automotive industry, Black Sesame Technologies has expanded into robotics and edge computing through its proprietary IP cores, algorithms, and software ecosystems. The company's Huashan A1000/A2000 and Wudang C1200 chip families deliver high performance, reliability and cost efficiency, serving as core computing engines for ADAS, robotics, edge AI and consumer electronics. These solutions have empowered leading global automotive OEMs and Tier 1 suppliers. At the exhibition, Black Sesame Technologies highlighted its comprehensive robotics solutions: Pre-designed SOM Boards: Powered by Huashan A1000/Wudang C1200 chips, providing scalable, energy-efficient hardware foundations that reduce development cycles Developer Kit/ Evaluation Board: Ready-to-use platforms with ROS1/ROS2 compatibility enabling rapid prototyping for SLAM navigation and multi-sensor fusion Turnkey Solutions: End-to-end services from chip selection to structural manufacturing Edge-side LLM AI: Industry-first solution enabling localized inference and autonomous decision-making Since establishing its Singapore subsidiary in 2018, Black Sesame Technologies has built a team covering R&D, technical support, and business development. As a global operations hub, the Singapore team provides full lifecycle support for Southeast Asian clients from chip integration to deployment. "Southeast Asia is an emerging frontier for robotics applications, with strong demand in industrial automation, smart logistics and urban mobility," said Dr. Xu Jin, General Manager of Black Sesame Technologies Singapore. "We deliver not just high-performance hardware, but also algorithm optimization and customized solutions to help customers overcome complex challenges." Black Sesame Technologies will continue expanding partnerships across Southeast Asia to scale robotics applications in smart manufacturing, service robotics, and smart cities. The company also demonstrated a logistics robot prototype powered by its Wudang C1200 chip featuring edge-LLM enabled autonomous navigation. Contact For business or technical inquiries:Black Sesame Technologies Pte. Ltd. (Singapore)Address: 01 Fusionopolis Walk, #04-05/06, Solaris South Tower, Singapore 138628Tel: +65 6908 2986Email: sg@bst.aiWebsite: https://www.blacksesame.com.cn
● 此次收購將協助系統單晶片（SoC）設計人員透過市場檢驗的時序約束管理能力來加速設計，並提高功能約束和結構約束的正確性 西門子數位工業軟體宣布收購 Excellicon 公司，將其用於開發、驗證及管理時序約束的領先軟體整合到西門子 EDA 的產品組合。此次收購將協助西門子提供實施和驗證流程領域的創新方法，使系統單晶片（SoC）設計人員能夠改善功耗、效能與面積（PPA）表現，加快設計速度，強化功能約束與結構約束的正確性，提升生產效率，並彌補當前工作流程中的關鍵缺口。 西門子收購 Excellicon 為 EDA 設計引入先進的時序約束能力 隨著設計複雜度的不斷提升，系統單晶片（SoC）的設計也在發生快速變革，工程師對於時序約束的管理需要貫穿整個設計流程，以滿足 PPA 及產品快速上市等要求。 西門子數位工業軟體西門子 EDA 執行長 Mike Ellow 表示：「有效的時序約束管理對於 SoC 的成功設計至關重要。Excellicon 的約束驗證與管理解決方案不僅能強化西門子現有 EDA 產品組合，更可以透過與 Questa、Tessent、Aprisa 及 PowerPro 等西門子 EDA 產品的協作，將我們的產品組合擴展到關鍵的市場領域。」 Excellicon 完善且經過市場檢驗的產品組合涵蓋時序約束創建、編譯、驗證、形式驗證及管理的全流程，並採用多模式方法將早期設計概念與物理實現相連接，為最佳化的布局規劃及時序的分區方案提供洞察。Excellicon 的時序約束驗證與管理技術與西門子解決方案的整合，將進一步強化實施與驗證流程。 Excellicon 執行長 Himanshu Bhatnagar 表示：「我們非常高興能夠加入西門子，將我們在時序約束管理領域的知識與專業技術帶給更廣泛的西門子 EDA 社群。我們的合作將打造更全面的流程管理，賦能客戶將強大的創新成果更快推向市場，克服日益複雜的 IC 挑戰。」 Excellicon 於 2009 年在美國拉古納山成立，專注於開發數位設計與驗證工作流程中的時序約束工具。此次收購預計將在幾週內完成，具體交易條款尚未揭露。 如需深入了解西門子 EDA 全面的工具軟體及服務，請參訪：http://www.siemens.com/eda
台北訊，2025 年 5 月 23 日 — Synaptics® 公司（那斯達克代碼：SYNA）宣布擴展其Veros無線產品線，推出首款專為物聯網（IoT）設計的 Wi-Fi® 7 系統單晶片（SoC）系列。此系列包括 SYN4390 和 SYN4384，具備高度擴充性，支援高達 320 MHz 頻寬，可實現 5.8 Gbps 的峰值速度與低延遲表現。這些三合一 SoC 整合了 Wi-Fi 7、藍牙® 6.0，以及 Zigbee/Thread，並支援 Matter 標準，設計上著重於降低系統成本與功耗。該系列產品鎖定需要長距離穩定效能的 IoT 應用，提供優異的使用者體驗，適用情境包括 8K 影音串流、互動式遊戲、安全監控、沉浸式 AR/VR，以及家庭與車用娛樂等。 Wi-Fi 7 的多重連線操作（MLO）技術，讓裝置能同時透過多個頻段（2.4 GHz、5 GHz、6 GHz）收發資料流，以支援低延遲、高可靠性連線與高傳輸率，特別適用於視訊通話與遊戲等即時應用。Synaptics 的架構提供一種具備高能源效率與成本效益的方式，實現 MLO 所帶來的優勢。 Synaptics 無線產品事業群資深副總裁暨總經理 Venkat Kodavati 表示：「Wi-Fi 7 在無線網路基礎設施中的採用日益增加，為我們擴展 Veros 產品線、進一步支援大量多元的 Wi-Fi 7 物聯網終端設備帶來了絕佳機會。我們提供一個多功能解決方案，將 Wi-Fi 7 的優勢帶入高效能、低功耗的 IoT 裝置中。結合我們 Astra 原生 AI 運算平台的整合便利性，我們預期開發者能更有效率地打造下一代的連網與 AI 賦能 IoT 產品，包含 Wi-Fi 感測等創新功能。」 ABI Research 預測，Wi-Fi 7 晶片組的年出貨量將在 2029 年突破 20 億顆，2024 至 2029 年間的年複合成長率（CAGR）將達 56%。 ABI Research 資深研究總監 Andrew Zignani 表示：「Wi-Fi 7 憑藉其頻寬、傳輸量與延遲方面的提升，正為連網裝置開啟一個更加豐富與高階的應用新時代。不過，各類產品在導入 Wi-Fi 7 時的需求有所不同，邊緣 IoT 所面臨的挑戰也與個人電腦或基礎設施應用截然不同。Synaptics 推出的多樣化 Wi-Fi 7 解決方案，正是針對這些特殊需求量身打造，涵蓋低功耗、多協定連接支援以及 AI 功能等關鍵特性。這些能力將是推動 Wi-Fi 7 在各種 IoT 領域廣泛應用的關鍵，預期未來數年內，年出貨量將達數十億台裝置。」 Wi-Fi 7 產品系列重點特色 這款 Wi-Fi 7 IoT 系列支援 Matter 標準，並採用三合一整合設計，具備 Wi-Fi、藍牙與Zigbee/Thread 的連接能力，實現異質無線環境中的高度互通性，使裝置可作為多功能家庭中樞，靈活運作於各種無線網路架構中。主要功能特色包括： ● 透過 2×2 + 2×2 多重連線操作（MLO）、320 MHz 頻寬與 4K QAM，實現高達 5.8 Gbps 的峰值速度 ● 整合射頻前端與電源管理 IC（PMIC），有效降低系統成本與功耗 ● 雙核心藍牙 6.0，支援 LE Audio、通道探測（Channel Sounding ）及 LE長距離傳輸 （Long Range） ● 支援 Matter 並內建 802.15.4無線通訊模組 ，啟用 Zigbee 與 Thread 網路功能 ● 整合 Arm 核心與記憶體，可將網路處理功能從主處理器卸載，以進一步降低整體系統耗電量 上市時間 SYN4390 現已上市銷售，SYN4384 現在以有限數量提供評估使用。更多資訊如下： ● 獲取產品圖片 ● 下載 SYN4390 和 SYN4384 產品簡介 ● 聯絡當地銷售代理 關於 Synaptics Incorporated Synaptics（納斯達克股票代碼：SYNA）正在推動邊緣 AI 創新，將 AI 更接近終端用戶，改變我們與智慧連接裝置互動的方式，無論是在家中、工作中還是在車載場景中。作為前瞻性產品創新者的首選合作夥伴，Synaptics 透過其尖端的 Synaptics Astra™ AI 原生嵌入式計算、Veros™ 無線連接和多模態感測解決方案為未來提供動力。我們正在使數位體驗變得更智慧、更快速、更直觀、更安全和更流暢。從觸控、顯示和生物識別到 AI 驅動的無線連接、影片、視覺、音訊、語音和安全處理，Synaptics 是推動下一代技術，持續最佳化人們生活、工作和娛樂的體驗的力量。關注 Synaptics 的 LinkedIn、 X 和Facebook，或訪問 www.synaptics.com。 前瞻性陳述 本新聞稿包含 1995 年《私人證券訴訟改革法案》意義範圍內的前瞻性聲明，包括但不限於與公司當前對 Veros™ 三合一連接產品組合產品和技術（包括 SYN461x）的預期效能和效益相關的當前預期和預測。此類聲明乃根據當前預期所作出，且可能因風險與不確定性而導致實際結果與預期出現重大落差。可能導致實際結果產生差異的因素包括公司成功向新市場（包括 Wi-Fi 和藍牙連接廣泛市場）提供這些產品解決方案的能力；公司對技術和策略投資的預期以及其預期時程或效益；以及公司最新年度報告 10-K 表格和最新季度報告 10-Q 表格的「風險因素」、「管理層對財務狀況和營運成果的討論和分析」和「業務」部分中確定的其他風險；以及公司證券交易委員會報告中不時確定的其他風險。對於本新聞稿中包含的任何前瞻性聲明，公司聲稱享有 1995 年《私人證券訴訟改革法案》中為前瞻性聲明提供的安全港保護，且公司不承擔公開更新或修改前瞻性聲明的義務，以反映新資訊或未來事件，除非法律要求。 Synaptics和Synaptics標誌是Synaptics在美國和/或其他國家的商標。所有其他標誌均為其各自所有者的財產。
A12 藝術空間
SoC
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
